What is Biocept?
Biocept, Inc. operates at the intersection of oncology and molecular diagnostics, specializing in the development and commercialization of clinically actionable assays. By leveraging its patented Target Selector technology, the company provides physicians with critical insights for monitoring cancer patients, including the detection of metastases in the central nervous system via the CNSide cerebrospinal fluid assay. Beyond its core oncology focus, Biocept has demonstrated operational agility by integrating molecular diagnostic capabilities to address public health requirements, such as large-scale COVID-19 RT-PCR testing. The firm's market position is defined by its ability to translate complex cellular analysis into actionable clinical data, serving a vital role in personalized medicine and patient care management.
How much funding has Biocept raised?
Biocept has raised a total of $96.8M across 12 funding rounds:
Series C
$3.6M
Series D
$2.3M
Debt
$1.2M
Stock Offering
$19M
Share Placement
$9.3M
Stock Offering
$13.3M
Stock Offering
$10M
Multiple Rounds
$26.1M
Series C (2010): $3.6M, investors not publicly disclosed
Series D (2010): $2.3M, investors not publicly disclosed
Debt (2011): $1.2M, investors not publicly disclosed
Stock Issuance/Offering (2014): $19M, investors not publicly disclosed
Share Placement (2017): $9.3M led by ROTH Capital Partners and Chardan Capital
Stock Issuance/Offering (2018): $13.3M, investors not publicly disclosed
Stock Issuance/Offering (2019): $10M, investors not publicly disclosed
Share Placement (2020): $9.2M, investors not publicly disclosed
Share Placement (2020): $6.6M, investors not publicly disclosed
Share Placement (2020): $10.3M, investors not publicly disclosed
Key Investors in Biocept
Needham Capital Partners
A nationally recognized investment banking and asset management firm focused on growth-oriented companies, providing comprehensive advisory and transaction services.
ROTH Capital Partners
Undisclosed investor participating in the funding round.
Chardan Capital
Undisclosed investor participating in the funding round.
What's next for Biocept?
With the recent strategic investment, Biocept is well-positioned to accelerate the commercial adoption of its liquid biopsy portfolio and expand the clinical utility of its CNSide platform. The company's forward-looking strategy likely involves scaling its diagnostic infrastructure to meet increasing demand for non-invasive cancer monitoring. By focusing on high-growth segments within the molecular diagnostics market, Biocept aims to solidify its competitive advantage, potentially driving further innovation in tumor-associated molecular marker detection and enhancing its overall enterprise value in the evolving landscape of precision oncology.
See full Biocept company page
